Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a phospholipid and docosahexaenoic acid (DHA). DHA is an omega-3 polyunsaturated fatty acid that is a major structural component of the human brain, retina, and other tissues. In this combination, DHA is incorporated into or delivered with phospholipids, which are essential components of cell membranes. The formulation aims to enhance the bioavailability and targeted delivery of DHA to tissues such as the brain. Mechanistically, DHA-containing phospholipids play critical roles in maintaining membrane fluidity and integrity, supporting neuronal function, modulating inflammation through specialized pro-resolving mediators (SPMs), and contributing to cardiovascular health. This type of combination may be used as a dietary supplement for neuroprotection or cardiovascular support[2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phospholipid + docosahexaenoic acid.